The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)
SynAct Pharma AB (publ) (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, announced that the European Patent Office (EPO) on 14 March 2025 has issued an intention to grant of a European Patent with claims covering the formulation of resomelagon (AP1189) currently undergoing development in clinical phase 2b.
In addition to the US patent recently issued covering the specific salt form under clinical development, the present European patent will issue in a complementary patent family covering the formulation of these salt forms and as such will fortify the protection of resomelagon and the drug product in development. The formulation patent will provide exclusivity in Europe for SynAct’s lead asset until 2042 in all uses.
“We have put thoughts and efforts into formulating resomelagon in a way that would be readily applicable in the indications we are pursuing and compliant with the properties of the drug. It is a pleasure to see that our innovative approach is being recognized and rewarded with a patent that will greatly add to the value of our lead asset,” said Thomas Boesen, COO at SynAct.
In brief, an “Intention to grant” means that the EPO intends to grant a European patent based on the patent application as currently on file and a final “Decision to grant” will be issued by the EPO when all formalities are adhered to. After grant the European patent will be converted into national rights in European jurisdictions.
“The improved patent protection remains an important element for strengthen our business development efforts further and is a key element in our strategy going forward,” said Jeppe Øvlesen CEO.